Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Stretch Mark Cream

Seattle Genetics To Present SGN-35 And Lintuzumab Clinical Data At The European Hematology Association Congress
Seattle Genetics, Inc. (Nasdaq:SGEN) announced that data from a phase I clinical trial evaluating every three week dosing of SGN-35 and a phase I clinical trial of lintuzumab (SGN-33) will be reported at the 14th Congress of the European Hematology Association (EHA) being held June 4-7, 2009 in Berlin, Germany. The abstracts are available from the EHA website at http://www.ehaweb.org.
generic viagra online
Obama Nominates Human Genome Veteran To Lead NIH
Dr. Francis S. Collins, the Yale-educated, guitar-strumming physician and geneticist who led the Human Genome Project, was nominated Wednesday to head the National Institutes of Health, the New York Times reports. "Dr. Collins"s selection, which had been rumored for weeks, was praised by top scientists and research advocacy organizations for whom the health institute is a crucial patron," the Times reports. He is expected to sail through Senate confirmation. Drugshop to buy zoloft online and other pills.
News of the day
A Feasible, Simple And Convenient Model For Study Of Rectal Carcinoma
The method of building a rabbit rectal VX2 carcinoma model by injecting the cell suspension of VX2 cells into the wall of the rectum guided by X-ray fluoroscopy is feasible. The advantages of the model are ease of establishment, short growth period, and high stability. The rectal VX2 carcinoma established in this rabbit model is similar to human rectal carcinoma in aspects of pathological representation, tumor development, and metastasis. It offers an ideal major animal model for the study of rectal carcinoma, and especially profits the study of the staging of rectal carcinoma in imaging.
Diagnostics

New UK Developed Anti-Bacterial Drug {Metallo-Porphyrin} Unveiled At Leading European Microbiology Congress

Yesterday"s 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) conference in Helsinki reported a significant addition to the dwindling number of drugs in the fight against the hospital "Superbug", Methicillin Resistant Staphylococcus aureus (MRSA). UK-based pharmaceutical company Destiny Pharma presented research into the rapid anti-bacterial activity of its latest platform of drugs against Staphylococcus aureus on the second day of the conference. Whilst the company"s lead anti-microbial XF-73 continues on course within Phase I/IIa clinical development, Destiny has now demonstrated the novel anti-bacterial mechanism of action of DPD-207. This is an example of its new platform of Metallo-Porphyrin (MP) drugs which has been proven to act in a similar manner to the XF drug platform. The XF drugs: 1. Kill bacteria extremely quickly (much faster than traditional antibiotics) 2. Bacteria such as MRSA seem unable to become resistant to XF/MP drug action (unlike many antibiotics to which the Superbug can rapidly become resistant) 3. Kill bacteria within biofilms (the protective "jelly" bacteria produce around themselves, which acts as a protective barrier against antibiotics) The MP drugs appear to share many of the same revolutionary and highly advantageous anti-bacterial properties of the XF drugs. The MP drug platform represents a significant expansion of the Destiny Pharma drug portfolio. More information about MRSA In the USA around 126,000 people are hospitalised each year with MRSA-related infections resulting in 19,000 fatalities. In the UK, MRSA causes over 6,000 serious bloodstream infections each year and results in at least 1,600 deaths. Healthcare-associated infections (HCAIs) predominantly caused by MRSA, are estimated to cost the NHS over ÷£1 billion every year and the US economy more than $30 billion More information about the XF series The XF compounds are bactericidal rather than bacteriostatic; killing the bacteria instead of just limiting population growth. These compounds have a unique structure based on a porphyrin core and are chemically distinct from all existing antimicrobial therapies. In laboratory studies, the XFs are active against a wide variety of clinically important gram-positive bacteria, including the most common and problematic MRSA strains and two clinical isolates of Clostridium difficile. Destiny Pharma


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009